Keywords: AstraZeneca, Iressa, NICE, NSCLC, Recentin, Colorectal cancer
Good and bad news for AstraZeneca, as UK’s NICE recommends Iressa for NSCLC on NHS, but firm drops Recentin as first-line in mCRC
Article | 28 May 2010
In draft guidance, published yesterday, the UK’s National Institute for Health and Clinical Excellence (NICE) recommended AstraZeneca’s Iressa ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
